# Pharmacokinetics of Oral Hydroxyurea Solution

> **NCT03763656** · PHASE1,PHASE2 · COMPLETED · sponsor: **Nova Laboratories Limited** · enrollment: 33 (actual)

## Conditions studied

- Sickle Cell Disease
- Sickle-Cell; Hemoglobin Disease, Thalassemia
- Sickle Cell-beta-thalassemia
- Sickle Cell Hemoglobin C

## Interventions

- **DRUG:** Oral Hydroxyurea (100 mg/mL) Solution

## Key facts

- **NCT ID:** NCT03763656
- **Lead sponsor:** Nova Laboratories Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-03
- **Primary completion:** 2021-05-19
- **Final completion:** 2021-12-29
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2024-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03763656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03763656, "Pharmacokinetics of Oral Hydroxyurea Solution". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03763656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*